Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 237

1.

Effectiveness of 23-valent polysaccharide pneumococcal vaccine on pneumonia in HIV-infected adults in the United States, 1998--2003.

Teshale EH, Hanson D, Flannery B, Phares C, Wolfe M, Schuchat A, Sullivan P.

Vaccine. 2008 Oct 29;26(46):5830-4. doi: 10.1016/j.vaccine.2008.08.032. Epub 2008 Sep 9.

PMID:
18786586
2.

Effectiveness of polysaccharide pneumococcal vaccine in HIV-infected patients: a case-control study.

Peñaranda M, Falco V, Payeras A, Jordano Q, Curran A, Pareja A, Samperiz G, Dalmau D, Ribera E, Riera M.

Clin Infect Dis. 2007 Oct 1;45(7):e82-7. Epub 2007 Aug 21.

PMID:
17806042
4.

A 5-year longitudinal follow-up study of serological responses to 23-valent pneumococcal polysaccharide vaccination among patients with HIV infection who received highly active antiretroviral therapy.

Hung CC, Chang SY, Su CT, Chen YY, Chang SF, Yang CY, Liu WC, Wu CH, Chang SC.

HIV Med. 2010 Jan;11(1):54-63. doi: 10.1111/j.1468-1293.2009.00744.x. Epub 2009 Jul 29.

5.

Pneumonia in HIV-infected patients in the HAART era: incidence, risk, and impact of the pneumococcal vaccination.

López-Palomo C, Martín-Zamorano M, Benítez E, Fernández-Gutiérrez C, Guerrero F, Rodríguez-Iglesias M, Girón-González JA.

J Med Virol. 2004 Apr;72(4):517-24.

PMID:
14981752
6.

Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy.

Abzug MJ, Pelton SI, Song LY, Fenton T, Levin MJ, Nachman SA, Borkowsky W, Rosenblatt HM, Marcinak JF, Dieudonne A, Abrams EJ, Pathak I; Pediatric AIDS Clinical Trials Group P1024 Protocol Team.

Pediatr Infect Dis J. 2006 Oct;25(10):920-9.

PMID:
17006288
7.

Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial.

Søgaard OS, Lohse N, Harboe ZB, Offersen R, Bukh AR, Davis HL, Schønheyder HC, Østergaard L.

Clin Infect Dis. 2010 Jul 1;51(1):42-50. doi: 10.1086/653112.

PMID:
20504165
8.

Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults.

Lesprit P, Pédrono G, Molina JM, Goujard C, Girard PM, Sarrazin N, Katlama C, Yéni P, Morineau P, Delfraissy JF, Chêne G, Lévy Y; ANRS 114-Pneumovac Study Group.

AIDS. 2007 Nov 30;21(18):2425-34.

PMID:
18025879
9.

Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study.

Vila-Córcoles A, Ochoa-Gondar O, Hospital I, Ansa X, Vilanova A, Rodríguez T, Llor C; EVAN Study Group.

Clin Infect Dis. 2006 Oct 1;43(7):860-8. Epub 2006 Aug 21.

PMID:
16941367
10.

Enhanced antibody response to pneumococcal polysaccharide vaccine after prior immunization with conjugate pneumococcal vaccine in HIV-infected adults.

Kroon FP, van Dissel JT, Ravensbergen E, Nibbering PH, van Furth R.

Vaccine. 2000 Nov 22;19(7-8):886-94.

PMID:
11115712
11.

Safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine in HIV-1 infected former drug users.

Amendola A, Tanzi E, Zappa A, Colzani D, Boschini A, Musher DM, Zanetti AR.

Vaccine. 2002 Nov 1;20(31-32):3720-4.

PMID:
12399200
12.

Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients.

Breiman RF, Keller DW, Phelan MA, Sniadack DH, Stephens DS, Rimland D, Farley MM, Schuchat A, Reingold AL.

Arch Intern Med. 2000 Sep 25;160(17):2633-8.

PMID:
10999977
13.

Impact of pneumococcal vaccination on the incidence of pneumonia by HIV infection status among patients enrolled in the Veterans Aging Cohort 5-Site Study.

Rodriguez-Barradas MC, Goulet J, Brown S, Goetz MB, Rimland D, Simberkoff MS, Crothers K, Justice AC.

Clin Infect Dis. 2008 Apr 1;46(7):1093-100. doi: 10.1086/529201.

14.

Response of human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy to vaccination with 23-valent pneumococcal polysaccharide vaccine.

Rodriguez-Barradas MC, Alexandraki I, Nazir T, Foltzer M, Musher DM, Brown S, Thornby J.

Clin Infect Dis. 2003 Aug 1;37(3):438-47. Epub 2003 Jul 22.

PMID:
12884170
15.

Serological response to pneumococcal vaccination in HAART-treated HIV-infected patients: one year follow-up study.

Falcó V, Jordano Q, Cruz MJ, Len O, Ribera E, Campins M, Crespo M, Ocaña I, Rodrigo MJ, Pahissa A.

Vaccine. 2006 Mar 24;24(14):2567-74. Epub 2005 Dec 27.

PMID:
16423429
16.
17.

The persisting burden of invasive pneumococcal disease in HIV patients: an observational cohort study.

Siemieniuk RA, Gregson DB, Gill MJ.

BMC Infect Dis. 2011 Nov 11;11:314. doi: 10.1186/1471-2334-11-314.

18.

Viral load response to a pneumococcal conjugate vaccine, polysaccharide vaccine or placebo among HIV-infected patients.

Goetz MB, Feikin DR, Lennox JL, O'Brien WA, Elie CM, Butler JC, Breiman RF.

AIDS. 2002 Jul 5;16(10):1421-3.

PMID:
12131220
19.

Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study.

Vila-Corcoles A, Salsench E, Rodriguez-Blanco T, Ochoa-Gondar O, de Diego C, Valdivieso A, Hospital I, Gomez-Bertomeu F, Raga X.

Vaccine. 2009 Mar 4;27(10):1504-10. doi: 10.1016/j.vaccine.2009.01.013. Epub 2009 Jan 24.

PMID:
19171174
20.

Impact of prior pneumococcal vaccination on clinical outcomes in HIV-infected adult patients hospitalized with invasive pneumococcal disease.

Imaz A, Falcó V, Peñaranda M, Jordano Q, Martínez X, Nadal C, Curran A, Planes AM, Dalmau D, Ribera E, Riera M, Ruiz de Gopegui E, Pahissa A.

HIV Med. 2009 Jul;10(6):356-63. doi: 10.1111/j.1468-1293.2009.00695.x. Epub 2009 Mar 11.

Supplemental Content

Support Center